

Teddy Network of Excellence

Funded under the Community's Sixth Framework Programme



FIRST EMEA WORKSHOP ON EUROPEAN PAEDIATRIC NETWORK

EMA, Conference Room 2°

16 February 2009

TEDDY Networking Experience (in the Paediatric Medicines Research Sector)



TEDDY

Task-force in Europe for Drug
Development for the Young



ADRIANA CECI, TEDDY NoE Coordinator

16 February 2009, 9.00-16.30

7, Westferry Circus, Canary Wharf, London E14 4HB

Teddy Network of Excellence

Funded under the Community's Sixth Framework Programme



TEDDY is a **Network of Excellence** funded under the 6th Framework Program, encompassing 19 Research Centers and 10 European Countries and Israel and is cooperating with more than 200 researchers and experts

Aimed at increasing availability of paediatric safe and efficacious drugs



TEDDY Task-force in Europe for Drugs Development for the Young

WHAT'S TEDDY?

TEDDY IS A NETWORK: A NEW RESEARCH INSTRUMENT

to straightening paediatric research and supporting both TEDDY Research groups and the existing external Networks, Societies and Experts to perform common and innovative initiatives including those that would be more difficult to execute in lack **of a supportive action.**

Networking is the core of the mission of TEDDY




TEDDY

Task force in Europe for Drugs Development for the Young

How is TEDDY fulfilling its obligations?

TEDDY NoE STRUCTURE



Networking has been one of the more relevant activities of TEDDY and has also facilitated the achievement of its main project results as **surveys, data banking, innovative methodologies identifications, inventories of researchers and research, and so on.**


Scientific Results

11 PR publications, 1 Monograph
3 Methodological testbooks, 1
Website , 3-monthly news-letters

ACTIVITIES AND PRINCIPAL RESULTS



Surveys, data collection and bibliographic searches have been used to picture the current situation as well as to identify research priorities



Common expertises, material and human resources have been exchanged and shared to plan Paediatric innovative research and methodologies



Disseminate and provide opinion on key documents and institutional rules and guidelines with reference to paediatric needs, methodological aspects, ethic, communication, etc



TEDDY

Task-force in Europe for Drugs Development for the Young

TEDDY Networking Methodology

- Contact and interconnect 'noncompeting' people having similar interest or concerns
 - **Search for sector of interest and knowledge**
- Create consensus on content and instruments to be used for common research
 - **Surveys- Focus Groups-Questionnaires**
- To circulate knowledge and skills along the 'points' and the 'nodes' of the Network
 - **Personel ecxhange,-e-learning courses , meeting participation, ecc**
- Favour relationship among interested parties



TEDDY

– Open Conferences-Working Groups

Task force in Europe for Drugs Development for the Young

NEDDY Networking

quality standards and recognition criteria



**Non-competitiveness
among participants**

Interest on the project

**Good communication
skills and
opportunities**

**To be in contact with the Paediatric Community
(scientific, authorities, professionals,
companies, associations, ecc)**

To deserve time and appropriate resources

**Existing Paediatric
Networks**

**Existing
Paediatric
Scientific
Societies**

**Regulatory Bodies
with Paediatric
vocation**



TEDDY

Task-force in Europe for Drugs Development for the Young

TEDDY Experts Groups

quality standards and recognition criteria



-2-

Experts should be expected to act in an independent manner

-3-

A diversity of view points should be assembled.

individuals outside partners' s habitual circle of contacts should be included

-1-

The quality of scientific expertise can be based on the excellence of scientists.

(number and impact of refereed publications)

However, it may also include practical knowledge.

TD~ RCM.001-September 2005

Expert Groups Start-Up Reference Guide

TD-WP04.001-November 2005

GUIDELINES ON SETTING UP THERAPEUTIC EXPERTS GROUPS: STANDARD OPERATING PROCEDURES (SOP)

TD-WP04.002-December 2005 THERAPEUTIC GROUPS ACTIVITIES




TEDDY

Task-force in Europe for Drugs Development for the Young

Source: Principles on the collection and use of expertise (EC 2002)

Succesful Networking activities

Collaborating Poeple



European Countries: 25


No European Countries: 8



TEDDY

Task force in Europe for Drugs Development for the Young

Successful Networking activities : Collaboration and partnerships with other networks / groups





Successful Networking activities


Defining off-label and unlicensed use of medicines for children: results of a Delphi survey.

The aim of this Delphi survey is to develop common definitions for unlicensed and off-label drug use in children to be used for research and regulatory purposes. After a literature review on the current status of unlicensed/off-label definitions, a two-stage, web-based Delphi survey was conducted among experts in Europe. Results were then consulted with the European Medicines Agency (EMA)

The lowest level of consensus reached was for questions related to a different formulation or if a drug was given although contraindicated. At the final step, 85% of the responding experts agreed on the proposed definition for off-label (use of a drug already covered by a Marketing Authorisation, in an unapproved way) and 80% on the definition for unlicensed.

Table 1: Composition of the Expert Panel

	Invited % (n)	participants % (n)
Health Professionals	14.29 (12)	20.59 (7)
Industry	8.33 (7)	8.82 (3)
Regulatory	20.24 (17)	14.71 (5)
Scientists	52.38 (44)	55.88 (19)
Other	4	0
Total	84	34



Task-force in Europe for Drugs Development for the Young

Successful Networking activities

Networking & Unmet Therapeutic Needs

The Paediatric Committee shall establish an **inventory of therapeutic needs**, with a view to **identifying research priorities**. The Agency shall make the inventory public at the latest by 26 January 2010

(Paed. Reg. art. 43)



One of the TEDDY key objective has been to **contribute to identify** unmet therapeutic needs

- assessing and profiling the current paediatric medicines uses
- identifying research priorities to meet therapeutic needs

This has been done by Setting up **Therapeutic Experts Groups (TEGs)**




TEDDY

Task force in Europe for Drugs Development for the Young

TEGs – Tasks and Cooperation

TASKS

- 1- circulate at large the EMEA Lists to experts
- 2- enlarge awareness
- 3- identify priorities and unmet needs
- 4- collect existing paediatric studies
- 4- favour clinical trials development



Cooperating with:

- PENTA
- PRINTO
- UNEPSA/EPA
- SIOP Europe
- European Paediatric Cardiology Association (AEPC),
- European Society for Paediatric Endocrinology (ESPE)
- European Society for Paediatric Infectious Diseases (ESPID)
- European Respiratory Society (ERS)
- Società Italiana per le Malattie Respiratorie Infantili (SIMRI)
- European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
- ESPGHAN Gastro-Intestinal Committee
- Società Italiana di Pediatria (SIP)
- Société Française de Pédiatrie
- Paediatric Spanish Society



TEDDY

Task force in Europe for Drugs Development for the Young

Succesful Networking activities

Networking & Unmet Therapeutic Needs

Recommendation for drug development for children

M. Catapano^a, C. Manfredi^a, P. Paolucci^b, H. Cross^c, K. Verhamme^d, M.J. Mellado Peña^e, I. Grosch-Wärner^f, C. Knibbe^g and A. Ceci^{a,*}

^aConsorzio per Valutazioni Biologiche e Farmacologiche, Pavia, Italy
^bDepartment of Mother and Child, University of Modena and Reggio Emilia, Modena, Italy
^cUniversity College London, London, UK
^dPharmacokinetics and Biostatistics, Erasmus University, Rotterdam, The Netherlands
^eDepartment of Paediatrics, Charité University Hospital, Berlin, Germany
^fDepartment of Paediatrics, University of Cologne, Cologne, Germany
^gDepartment of Paediatrics, University of Cologne, Cologne, Germany

THE CHALLENGES OF THE NEW EU PHARMACEUTICAL LEGISLATION

PHARMACEUTICALS POLICY AND LAW

Keywords: ...

1. Intro...


The Pa... establishes...

* Correspondence: A. Ceci, Via Palestro 15, 27100 Pavia, Italy. E-mail: ceci@unipv.it

PK/Dosage/Efficacy & Safety (extension to paediatric ages)		PK/Dosage/Efficacy & Safety (new indic.)	Age appropriate formulations	
Adenosine TP	Iloprost	Atorvastatin	Metoprolol	Low Molecular Weight Heparins
Alteplase	Inhaled Nitric Oxide	Colesevelam	Acebutolol	Warfarin
Amiodarone	Irbesartan	Fluvastatin	Esmolol	Indometacin
Amlodipine	Labetalol	Hydrochlorothiaz / Chloroth	Amiodarone	Clonidine
Arginine-Vasopressin	Levosimendan	Lovastatin	Flecainide	Labetalol
Atenolol	Lidocaine, as antiarrhythmic	Pravastatin	Adenosine Tp	Milrinone
Atorvastatin	Lovastatin	Simvastatin	Lidocaine	Sildenafil
Bosentan	Low Molecular Heparin		Furosemide	Iloprost
Candesartan	Metoprolol		Spirololactone	Dopamine
Captopril	Milrinone		Hydrochlorothiaz / Chloroth	Dobutamine
Carvedilol	Nicardipine		Irbesartan	Arginine-Vasopressin
Clonidine	Nifedipine		Candesartan	Di/Hydralazine
Clopidogrel	Nitroglycerine		Valsartan	Nitroprussiate Na
Colesevelam	Pravastatin		Atorvastatin	Captopril
Dalteparine	Prazosin		Fluvastatin	Ramipril
Di/hydralazine	Propafenone		Urokinase	Nifedipine
Dipyridamole	Propranolol		Clopidogrel	Verapamil
Dopamine	Ramipril		Alteplase	Amlodipine
Enalapril	Sildenafil		Enoxaparine	Nicardipine
Enoxaparine	Simvastatin		Dalteparine	Prazosin
Esmolol	Sotalol		Acetylsalicylic Acid (Aspirin)	Propranolol
Flecainide	Telmisartan		Heparin	Sotalol
Fluvastatin	Urokinase			Carvedilol
Furosemide	Valsartan			Atenolol
Hydrochlorothiaz / Chloroth	Verapamil			
	Warfarin			

150 Experts in Europe

13 Therapeutic areas - 478 drugs



Task-force in Europe for Drugs Development for the Young



Successful Networking activities

Collecting pediatric data in the EU for pharmacoepidemiology and pharmacovigilance

**Assessment of 16 databases
from 10 EU Countries
8 million children**


	Cohort Case-Control Studies	Drug indication studies	IMS DA UK	Pediatr UK	IPCI	GPRD	THIN Data	GRESEA RCH	SPICE	IMS DA FRANCE	IMS DA AUSTRIA	IMS DA GERMANY	PHARMO	ADB	The Danish Prescription Database (NPD)	Finland prescription register	Swedish Medical Birth Register
Unique identifier	yes	no	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
Age	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
Gender	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
Death	yes	no	yes	yes	yes	yes	yes	yes	yes	yes	no	yes	yes	no	no	yes	limited
Prescriptions	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
Unique product code	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
ATC Code	yes	yes	yes	yes	yes	no	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
Date of prescription	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	no	yes	no
Dosage of prescription	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	no	yes	yes
Duration of prescription	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	no	yes	yes
Laboratory values	yes	no	yes	yes	yes	yes	yes	yes	no	yes	yes	yes	yes	no	no	no	yes
Diagnostic data (e.g. x-ray, MRI, etc.)	yes	no	yes	yes	yes	yes	yes	yes	no	yes	yes	yes	yes	no	no	no	yes
Treatment outcome	yes	no	yes	yes	yes	yes	yes	yes	no	no	no	no	yes	no	no	no	yes
Hospital admission	yes	no	yes	yes	yes	yes	yes	yes	no	no	yes	yes	yes	no	no	no	yes
Hospital discharge	yes	no	no	yes	yes	yes	yes	yes	no	no	no	no	yes	no	no	no	yes
Referral to specialist	yes	no	yes	yes	yes	yes	yes	yes	no	no	yes	yes	yes	no	no	no	yes
Results of referral	yes	no	yes	yes	yes	yes	no	yes	no	no	no	no	yes	no	no	no	yes
Diagnosis	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	no	no	no	yes
Medical history (anamnesis)	yes	no	yes	yes	yes	yes	yes	yes	yes	no	no	no	yes	no	no	no	no
Vaccination	yes	no	yes	yes	yes	yes	yes	yes	yes	no	no	no	yes	no	yes	no	no
Allergies	yes	no	yes	no	yes	yes	yes	yes	yes	no	no	no	yes	no	no	no	no
Indication for prescription	yes	no	yes	no	yes	yes	yes	yes	yes	no	yes	yes	no	no	no	no	no
Height	yes	no	yes	yes	yes	yes	yes	yes	yes	no	no	no	yes	no	no	no	yes
Weight	yes	no	yes	yes	yes	yes	yes	yes	yes	no	no	no	yes	no	no	no	yes
Environmental and life-style characteristics	yes	no	yes	yes	yes	yes	yes	yes	yes	no	no	no	yes	no	no	no	yes
Access to raw data	yes	no	yes	no	yes	yes	yes	yes	no	yes	yes	yes	yes	no	no	yes	yes
Access to original medical charts	yes	no	no	yes	yes	yes	no	no	no	no	no	no	yes	no	yes	no	no

Databases for pediatric medicine research in Europe--
assessment and critical appraisal. **Pharmacoepidemiol
Drug Saf. 2008 Dec;17(12):1155-67.**



Task force in Europe for Drugs Development for the Young

**Drug use in children: cohort study in three
European countries. **BMJ. 2008 Nov
24;337:a2245. doi: 10.1136 / bmj.a2245.****



**Asthma drug use in children in the
Netherlands, Italy and United Kingdom
(E. Fatma. Sen, et al submitted)**

**The Prescribing of analgesics and Non-
Steroidal Anti-Inflammatory Drugs in
Paediatric Primary Care in the UK, Italy and
the Netherlands (Antje Neubert¹, et al)**

Successful Networking activities

European Surevy on ethical and legal framework,

Journal International de Bioéthique, sept. 2008, vol.19, n.3, pp.17-48.

A survey investigating the ethical and legal context in European Countries has demonstrated a jeopardised situation regarding consent, assent, general awareness on ethic rules to be applied.

Question on:

1. Selection criteria (only direct benefit?)
2. Authorization/assent procedure (relevance of the minor opinion)
3. Information and privacy (any information according to the minor's capacity)
4. Emergency situation

27 European Countries
participated the Survey

770 Questionnaires further circulated

Res/Paed	202
Pharma I.	167
Other	33

Teddy Network of Excellence

Funded under the Community's Sixth Framework Programme



EUROPEAN SYMPOSIUM

Ethics and paediatric clinical research in Europe



Task-force in Europe for Drugs Development for the Young



CONCLUSIONS

- Networking in the Paediatric Research sector is well accepted and represent au useful tool
- Collaboration with Existing Networks, Regulatory Bodies, Professional Associations, Pharmaceutical Industry, Patients/parents Associations is possible
- Multidisciplinarity and Multisectoriality of participants lead to building up critical mass of capacities and knowledge
- *Existing quality standards and recognition criteria could be applied but need case by case adaptation*



TEDDY

Task force in Europe for Drugs Development for the Young



TANKS!



TEDDY

Task force in Europe for Drugs Development for the Young